Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

International Journal of Clinical Practice

Volumn 68, Issue 9, 2014, Pages 1152-1160

  Treuer, T ^a   Feng, Q ^b   Desaiah, D ^a   Altin, M ^a   Wu, S ^c   El Shafei, A ^d   Serebryakova, E ^a   Gado, M ^e   Faries, D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

^c Eli Lilly Asia Inc   (China)

^d Eli Lilly Suisse SA   (United Arab Emirates)

^e King Fahd Medical City   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PROPYLAMINE;

ADOLESCENT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHINA; DRUG RESPONSE; DRUG WITHDRAWAL; EGYPT; FEMALE; HUMAN; LEBANON; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHOBIA; PREDICTION; REMISSION; RUSSIAN FEDERATION; SEX DIFFERENCE; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; UNITED ARAB EMIRATES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; PROSPECTIVE STUDY;

ADOLESCENT; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHINA; EGYPT; FEMALE; HUMANS; LEBANON; MALE; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; RUSSIA; TAIWAN; TREATMENT OUTCOME; UNITED ARAB EMIRATES;

EID: 84908125142     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12437     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press, 2000.
2. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164(6): 942-8.
3. Willcutt EG. The prevalence of DSM-IV attention- deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9(3): 490-9.
4. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194(3): 204-11.
5. Martényi F, Treuer T, Gau SS et al. Attentiondeficit/ hyperactivity disorder diagnosis, co-morbidities, treatment patterns, and quality of life in a pediatric population in central and eastern Europe and Asia. J Child Adolesc Psychopharmacol 2009; 19(4): 363-76.
6. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2004; 24(1): 24-9.
7. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006; 8(4): 4.
8. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis CMAJ 2001; 165(11): 1475-88.
9. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 2002; 27(5): 699-711.
10. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83.
11. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo- controlled studies. Biol Psychiatry 2003; 53(2): 112-20.
12. Spencer T, Biederman J, Heiligenstein J et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(3): 251-65.
13. World Health Organization (2003). Adherence to Long-term Therapies: Evidence for Action. http:// www.who.int/chp/knowledge/publications/adherence-report/en/ (accessed 22 July 2013).
14. Barkley RA. Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood. Postgrad Med 2008; 120(3): 48-59.
15. Hong J, Novick D, Treuer T et al. Predictors and consequences of adherence in the treatment of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Central Europe and East Asia. Patient Prefer Adherence 2013; 30(7): 987-95.
16. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004; 10(2): 122-9.
17. Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention- deficit hyperactivity disorder. J Psychopharmacol 2012; 26(6): 753-65.
18. Hodgkins P, Dittmann RW, Sorooshian S, Banaschewski T. Individual treatment response in attention- deficit/hyperactivity disorder: broadening perspectives and improving assessments. Expert Rev Neurother 2013; 13(4): 425-33.
19. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/ hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 2009; 48(5): 511-8.
20. Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health 2011; 11(5): 14.
21. Block SL, Williams D, Donnelly CL, Dunn DW, Saylor KE, Ruberg SJ. Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. Clin Pediatr (Phila) 2010; 49(8): 768-76.
22. Chazan R, Borowski C, Pianca T, Ludwig H, Rohde LA, Polanczyk G. Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention-deficit/ hyperactivity disorder? A naturalistic study from a developing country. J Clin Psychopharmacol 2011; 31(3): 309-17.
23. Chen CY, Yeh HH, Chen KH, Chang IS, Wu EC, Lin KM. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2011; 21(3): 265-73.
24. Altin A, El-Shafei AA, Yu M et al. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries. Drugs in Context 2013; 2013, 212260. ISSN 1740-4398.
25. Zavadenko NN, Suvorinova Slu. [Therapeutic efficacy of nootropil different doses in attention deficit hyperactivity disorder]. Zh Nevrol Psikhiatr Im S S Korsakova 2004; 104(3): 32-7.
26. Zavadenko NN, Suvorinova NI. Attention-deficit hyperactivity disorder: determination of the optimal medical treatment duration. Zh Nevrol Psikhiatr Im S S Korsakova 2011; 111(10 Pt 1): 28-32.
27. Riley AW, Forrest CB, Rebok GW et al. The Child Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004; 42(3): 221-31.
28. Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004; 42(3): 210-20.
29. Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry 2006; 15(Suppl. 1): I63-71.
30. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 2006; 16(3): 286-97.
31. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40(8): 922-8.
32. Firestone P. Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry 1982; 52(3): 447-57.
33. Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation. Psychopharmacol Bull 1985; 21(1): 28-36.
34. Ibrahim el SR. Rates of adherence to pharmacological treatment among children and adolescents with attention deficit hyperactivity disorder. Hum Psychopharmacol 2002; 17(5): 225-31.
35. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004; 43(5): 559-67.
36. Hong JH, Novick D, Treuer T et al. Predictors and consequences of adherence in the treatment of pediatric patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in Central Europe and East Asia. Poster presented at: 11th World Congress of Biological Psychiatry, June 23-27, 2013Kyoto, Japan.
37. Hong JH, Novick D, Treuer T et al. Patient characteristics associated with treatment initiation among paediatric patients newly diagnosed with attention deficit hyperactivity disorder (ADHD) in Central Europe and Eastern Asia. Poster presented at: 4th World Congress on ADHD, June 6-9, 2013, Milan, Italy.
38. Hong JH, Novick D, Treuer T et al. Association between 6-week response and subsequent remission in the treatment of paediatric patients with attention deficit hyperactivity (ADHD) symptoms in Central Europe and Eastern Asia. Poster presented at: 4th World Congress on ADHD, 2013 June 6-9, Milan, Italy.